<ul data-eligibleForWebStory="false"><li>Anthem Biosciences IPO received a lukewarm response on its opening day, with retail investors showing the strongest interest.</li><li>The issue, priced between ₹540-570, saw retail investors subscribing 0.22 times, while QIBs had minimal participation at 0.00 times and non-institutional investors at 0.36 times.</li><li>Anthem Biosciences, a Bengaluru-based CRDMO company, has achieved a ₹1,000 crore revenue milestone in 14 years and demonstrated a strong financial performance, growing at a 32% CAGR to ₹1,845 crore between FY23 and FY25.</li><li>SBI Securities recommended subscribing to the IPO for a long-term horizon, citing the company's service capabilities, expansion plans, 242-project pipeline, and revenue from potential blockbuster drugs.</li></ul>

Anthem Biosciences IPO gets lukewarm response on opening day

Discover more